Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Income (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Operating Income for 7 consecutive years, with -$22.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income fell 16.8% to -$22.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$84.8 million, a 18.99% increase, with the full-year FY2025 number at -$84.8 million, down 287.13% from a year prior.
  • Operating Income was -$22.7 million for Q4 2025 at Fulcrum Therapeutics, down from -$21.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$17.0 million in Q1 2021 to a low of -$34.2 million in Q2 2022.
  • A 5-year average of -$23.6 million and a median of -$22.3 million in 2025 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: tumbled 73.94% in 2022, then surged 31.61% in 2025.
  • Fulcrum Therapeutics' Operating Income stood at -$23.6 million in 2021, then crashed by 45.32% to -$34.2 million in 2022, then increased by 19.85% to -$27.4 million in 2023, then increased by 29.19% to -$19.4 million in 2024, then dropped by 16.8% to -$22.7 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Operating Income are -$22.7 million (Q4 2025), -$21.9 million (Q3 2025), and -$19.8 million (Q2 2025).